Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.53 |
| ▸ | MAOB | P27338 | 14/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444081 | 1.00 | AOC3 (0.53) | AOC3MAOBPDE10AHSD17B10NPC1 | |
| SCHEMBL1444077 | 1.00 | AOC3 (0.53) | AOC3MAOBPDE10AHSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL3752553 | 0.99 | AOC3 (0.52) | AOC3MAOBPDE10AHSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL2923134 | 0.99 | AOC3 (0.52) | AOC3MAOBPDE10AHSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL2923136 | 0.99 | AOC3 (0.52) | AOC3MAOBPDE10AHSD17B10NPC1 | |
| SCHEMBL3751561 | 0.90 | AOC3 (0.53) | AOC3MAOBLMNAMAPT | |
| SCHEMBL3751565 | 0.90 | AOC3 (0.53) | AOC3MAOBLMNAMAPT | |
| SCHEMBL3751556 | 0.90 | AOC3 (0.53) | AOC3MAOBLMNAMAPT | |
| Hydrochloric Acid SCHEMBL2923493 | 0.89 | AOC3 (0.52) | AOC3MAOBLMNAMAPT | |
| Hydrochloric Acid SCHEMBL3763018 | 0.89 | AOC3 (0.52) | AOC3MAOBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | claimed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | claimed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | claimed |
| EP-2222160-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | Pharmaxis Ltd. (AU) | 2010-09-01 | — | — | EP | claimed |
| WO-2009066152-A2 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (US) | 2009-05-28 | — | — | WO | claimed |
| US-10576148-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2020-03-03 | — | — | US | disclosed |
| US-20180071388-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2018-03-15 | — | — | US | disclosed |
| EP-2475387-B1 | VAP-1 INHIBITORS FOR USE IN TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP (FI) | 2017-11-01 | — | — | EP | disclosed |
| US-9795671-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2017-10-24 | — | — | US | disclosed |
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-20130195883-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2013-08-01 | — | — | US | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2475387-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | Biotie Therapies Corp. (FI) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029996-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2011-03-17 | — | — | WO | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | AOC3 30/4885MAOB 295/4885PDE10A 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.